|
1
|
Cernea S, Dima L, Correll CU and Manu P:
Pharmacological management of glucose dysregulation in patients
treated with second-generation antipsychotics. Drugs. 80:1763–1781.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Holt RIG: Association between
antipsychotic medication use and diabetes. Curr Diab Rep.
19(96)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pillinger T, Beck K, Gobjila C, Donocik
JG, Jauhar S and Howes OD: Impaired glucose homeostasis in
first-episode schizophrenia: A systematic review and meta-analysis.
JAMA Psychiatry. 74:261–269. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pillinger T, Beck K, Stubbs B and Howes
OD: Cholesterol and triglyceride levels in first-episode psychosis:
Systematic review and meta-analysis. Br J Psychiatry. 211:339–349.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Teasdale SB, Ward PB, Jarman R, Wade T,
Rossimel E, Curtis J, Lappin J, Watkins A and Samaras K: Is obesity
in young people with psychosis a foregone conclusion? Markedly
excessive energy intake is evident soon after antipsychotic
initiation. Front Psychiatry. 9(725)2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Rummel-Kluge C, Komossa K, Schwarz S,
Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM and Leucht S:
Head-to-head comparison of metabolic side effects of second
generation antipsychotics in the treatment of schizophrenia: A
systematic review and meta-analysis. Schizophr Res. 123:225–233.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Dipasquale S, Pariante CM, Dazzan P,
Aguglia E, McGuire P and Mondelli V: The dietary pattern of
patients with schizophrenia: A systematic review. J Psychiatr Res.
47:197–207. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Polcwiartek C, Kragholm K, Rohde C,
Hashemi N, Vang T and Nielsen J: Diabetic ketoacidosis and diabetes
associated with antipsychotic exposure among a previously
diabetes-naive population with schizophrenia: A nationwide nested
case-control study. Diabetologia. 60:1678–1690. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Leslie DL and Rosenheck RA: Incidence of
newly diagnosed diabetes attributable to atypical antipsychotic
medications. Am J Psychiatry. 161:1709–1711. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Miron IC, Baroana VC, Popescu F and Ionica
F: Pharmacological mechanisms underlying the association of
antipsychotics with metabolic disorders. Curr Health Sci J.
40:12–17. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Silvestre JS and Prous J: Research on
adverse drug events. I. Muscarinic M3 receptor binding affinity
could predict the risk of antipsychotics to induce type 2 diabetes.
Methods Find Exp Clin Pharmacol. 27:289–304. 2005.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Weston-Green K, Huang XF and Deng C:
Second generation antipsychotic-induced type 2 diabetes: A role for
the muscarinic M3 receptor. CNS Drugs. 27:1069–1080.
2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang JP, Lencz T, Zhang RX, Nitta M,
Maayan L, John M, Robinson DG, Fleischhacker WW, Kahn RS, Ophoff
RA, et al: Pharmacogenetic associations of antipsychotic
drug-related weight gain: A systematic review and meta-analysis.
Schizophr Bull. 42:1418–1437. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Goh KK, Chen CY, Wu TH, Chen CH and Lu ML:
Crosstalk between schizophrenia and metabolic syndrome: The role of
oxytocinergic dysfunction. Int J Mol Sci. 23(7092)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Cheng SC, Goh KK and Lu ML: Metabolic
disturbances associated with antipsychotic drug treatment in
patients with schizophrenia: State-of-the-art and future
perspectives. World J Psychiatry. 11:696–710. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
del Campo A, Bustos C, Mascayano C,
Acuña-Castillo C, Troncoso R and Rojo LE: Metabolic syndrome and
antipsychotics: The role of mitochondrial fission/fusion imbalance.
Front Endocrinol (Lausanne). 9(144)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Vasiliu O: Case report: Cariprazine
efficacy in young patients diagnosed with schizophrenia with
predominantly negative symptoms. Front Psychiatry.
12(786171)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Mailman RB and Murthy V: Third generation
antipsychotic drugs: Partial agonism or receptor functional
selectivity? Curr Pharm Des. 16:488–501. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Vasiliu O, Vasile D and Voicu V: Efficacy
and tolerability of antibiotic augmentation in schizophrenia
spectrum disorders-A systematic literature review. Rom J Military
Med. CXXIII:3–20. 2020.
|
|
20
|
Vasiliu O and Vasile D: Risk factors and
quality of life in late-life depressive disorders. Rom J Military
Med. CXIX:24–28. 2016.
|
|
21
|
Brown E, Wilding JPH, Barber TM, Alam U
and Cuthbertson DJ: Weight loss variability with SGLT2 inhibitors
and GLP-1 receptor agonists in type 2 diabetes mellitus and
obesity: Mechanistic possibilities. Obes Rev. 20:816–828.
2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Pereira MJ and Eriksson JW: Emerging role
of SGLT-2 inhibitors for the treatment of obesity. Drugs.
79:219–230. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lee PC, Ganguly S and Goh SY: Weight loss
associated with sodium-glucose cotransporter-2 inhibition: A review
of evidence and underlying mechanisms. Obes Rev. 19:1630–1641.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ribola FA, Cançado FB, Schouveri JH, De
Toni VF, Medeiros VH and Feder D: Effects of SGLT2 inhibitors on
weight loss in patients with type 2 diabetes mellitus. Eur Rev Med
Pharmacol Sci. 21:199–211. 2017.PubMed/NCBI
|
|
25
|
Frampton JE: Empagliflozin: A review in
type 2 diabetes. Drugs. 78:1037–1048. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Deeks ED and Scheen AJ: Canagliflozin: A
review in type 2 diabetes. Drugs. 77:1577–1592. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Dhillon S: Dapagliflozin: A review in type
2 diabetes. Drugs. 79:1135–1146. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Liu L, Shi FH, Xu H, Wu Y, Gu ZC and Lin
HW: Efficacy and safety or ertugliflozin in type 2 diabetes: A
systematic review and meta-analysis. Front Pharmacol.
12(752440)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Shi Y, Si Y, Fu R, Zhang M, Jiang K, Dai
W, Shen J, Li X and Yuan Y: Efficacy and safety of SGLT-2i in
overweight/obese, non-diabetic individuals: A meta-analysis of
randomized controlled trials. Endokrynol Pol. 73:71–80.
2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Cho YK, Kim YJ and Jung CH: Effect of
sodium-glucose cotransporter 2 inhibitors on weight reduction in
overweight and obese populations without diabetes: A systematic
review and a meta-analysis. J Obes Metab Syndr. 30:336–344.
2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ashraf GM, Alghamdi BS, Alshehri FS, Alam
MZ, Tayeb HO and Tarazi FI: Empagliflozin effectively attenuates
olanzapine-induced body weight gain in female Wistar rats. Front
Pharmacol. 12(578716)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Cooper SJ and Reynolds GP: With expert
co-authors (in alphabetical order). Barnes T, England E, Haddad PM,
Heald A, Holt R, Lingford-Hughes A, Osborn D, et al: BAP guidelines
on the management of weight gain, metabolic disturbances and
cardiovascular risk associated with psychosis and antipsychotic
drug treatment. J Psychopharmacol. 30:717–748. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lally J, O'Loughlin A, Stubbs B, Guerandal
A, O'Shea D and Gaughran F: Pharmacological management of diabetes
in severe mental illness: A comprehensive clinical review of
efficacy, safety, and tolerability. Expert Rev Clin Pharmacol.
11:411–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Remington GJ, Teo C, Wilson V, Chintoh A,
Guenette M, Ahsan Z, Giacca A and Hahn MK: Metformin attenuates
olanzapine-induced hepatic, but not peripheral insulin resistance.
J Endocrinol. 227:71–81. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Luo C, Wang X, Huang H, Mao X, Zhou H and
Liu Z: Effect of metformin on antipsychotic-induced metabolic
dysfunction: The potential role of gut-brain axis. Front Pharmacol.
10(371)2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hsu WH, Hsiao PJ, Lin PC, Chen SC, Lee MY
and Shin SJ: Effect of metformin on kidney function in patients
with type 2 diabetes mellitus and moderate chronic kidney disease.
Oncotarget. 9:5416–5423. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Barbosa M and Fernandes V: Rapid-onset
clozapine-induced hyperglycemia: Pathways of glycaemic
dysregulation. BMJ Case Rep. 14(e243938)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Foldemo A, Wӓrdig R, Bachrach-Lindström M,
Edman G, Holmberg T, Lindström T, Valter L and Osby U:
Health-related quality of life and metabolic risk in patients with
psychosis. Schizophr Res. 152:295–299. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Agarwal SM and Stogios M: Cardiovascular
health in severe mental illness: Potential role for metformin. J
Clin Psychiatry. 83(22ac14419)2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Lao X, Ye H and Si T: A review of
switching strategies for patients with schizophrenia comorbid with
metabolic syndrome or metabolic abnormalities. Neuropsychiatr Dis
Treat. 17:453–469. 2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Halimi S and Vergès B: Adverse effects and
safety of SGLT-2 inhibitors. Diabetes Metab. 40 (Suppl.1):S28–S34.
2014.PubMed/NCBI View Article : Google Scholar
|
